Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Evotec, a company into discovery and development of novel small molecule drugs with operational sites in Europe and Asia, has reported revenues of EUR9.8m for the first quarter ended March 31, 2010, an increase of 19%, compared to EUR8.2m for the comparable period in 2009.
Subscribe to our email newsletter
Evotec has posted a net loss of EUR1.2m for the first quarter 2010, or EUR 0.01 per diluted share, compared to EUR21.8m, or EUR 0.21 per diluted share, for the comparable period in 2009.
Operating loss was EUR1.4m, compared to EUR20.2m for the comparable period in 2009.
Evotec said that the total group revenues before out-licensing income are expected to grow by at least 15%. These assumptions are based on the strong order book of approximately EUR30m at the end of March 2010, compared to EUR24m in 2009, expected new contracts and contract extensions as well as the achievement of certain milestones.